A Phase 1 Trial of the Combination of Everolimus (RAD001) and Bortezomib (VELCADE) for Relapsed or Refractory Lymphoma

Trial Profile

A Phase 1 Trial of the Combination of Everolimus (RAD001) and Bortezomib (VELCADE) for Relapsed or Refractory Lymphoma

Discontinued
Phase of Trial: Phase I

Latest Information Update: 31 Oct 2015

At a glance

  • Drugs Bortezomib (Primary) ; Everolimus (Primary)
  • Indications B cell lymphoma; Chronic lymphocytic leukaemia; Follicular lymphoma; Hairy cell leukaemia; Mantle-cell lymphoma; Waldenstrom's macroglobulinaemia
  • Focus Adverse reactions
  • Most Recent Events

    • 27 Oct 2015 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov record.
    • 16 Jul 2013 Planned end date changed from 1 May 2013 to 1 Nov 2013 as reported by ClinicalTrials.gov.
    • 12 Jun 2012 Additional lead trial investigator (Brian Hill) identified as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top